Hologic Inc. is a global medical technology company focused on improving women's health through the development and delivery of innovative products and solutions. The company specializes in diagnostic, surgical, and medical imaging systems, with a particular emphasis on breast health, cervical health, and skeletal health. Hologic's offerings include advanced molecular diagnostics, imaging systems for breast cancer detection, and various surgical instruments and techniques that enhance patient care. With a commitment to advancing health outcomes for women, Hologic actively invests in research and development to address unmet medical needs and improve access to vital healthcare solutions. Read More
Medical technology company Hologic (NASDAQ:HOLX) missed Wall Street’s revenue expectations in Q4 CY2025 as sales rose 2.5% year on year to $1.05 billion. Its non-GAAP profit of $1.04 per share was 5.4% below analysts’ consensus estimates.
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 27, 2025. The Company reported revenue of $1,047.8 million, GAAP diluted EPS of $0.79, and non-GAAP diluted EPS of $1.04.
The US credit market has entered 2026 with a level of momentum unseen in nearly a decade, as a powerful combination of multi-billion dollar mergers and a resurgence in leveraged buyouts (LBOs) drives primary issuance to record heights. Following the Federal Reserve’s pivot toward a more accommodative stance in
As of January 23, 2026, the global financial landscape is witnessing what many analysts are calling a structural "renaissance" in private equity. Led by industry titans Blackstone (NYSE: BX) and KKR & Co. Inc. (NYSE: KKR), the sector has shifted from a two-year period of high-interest-rate hibernation to a state of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately
as healthcare stocks have returned 21.1% over the past six months, topping the S&P 500 by 10.6 percentage points.
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2026 on Thursday, January 29, after the market closes.
The "exit logjam" that defined the global financial landscape for nearly three years has officially broken. As of January 15, 2026, the private equity (PE) and venture capital (VC) markets are experiencing what analysts call "The Great Unlocking"—a massive resurgence in liquidity events driven by stabilized interest rates, recovering
As 2026 begins, the healthcare sector is undergoing its most profound transformation in decades. Driven by a relentless push toward "precision medicine" and the industrialization of artificial intelligence, the industry has seen a staggering 150.5% year-over-year jump in deal value. The catalyst for this explosive growth was a blockbuster
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced the launch of Ultimate Defense, a new educational campaign in the U.S. with women’s professional basketball player Erica Wheeler. The initiative aims to increase awareness about the importance of routine cervical cancer screening and encourage women to talk with their healthcare providers about staying up to date with recommended care, a particularly urgent need at a time when many women are behind on preventive screenings.
When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
With margins holding firm, cash piling up, and AI services quietly compounding, this buy looks less like a quick trade and more like a conviction call hiding in plain sight.
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the medical devices & supplies - imaging, diagnostics stocks, including Hologic (NASDAQ:HOLX) and its peers.
BALA CYNWYD, Pa., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Hologic, Inc. (Nasdaq: HOLX), a leading medical technology company dedicated to improving women’s health, today announced new data that highlights how the company’s advanced AI-powered mammography solution can aid in detecting more breast cancers.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
While Hologic has underperformed the Nasdaq over the past year, it has notably outperformed in recent months, but analysts still remain cautious about the stock’s prospects.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
BALA CYNWYD, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
